In Reply Neither Messrs Slafsky and Davis nor Drs Swain and Ward address the merits of the principle espoused in the Viewpoint, which is that when drugs are provided at a discount to institutions caring for cancer patients, those discounts should be passed on to the patients and their insurers. Currently, 340B hospitals get drugs at a discount, yet bill patients and insurers as if the drugs were obtained at full price.
We proposed 2 possible improvements: either scale down the program and limit drug discounts to patients who are poor or uninsured or keep the program at its current scale and pass on the savings to patients and their insurers if they are treated at a 340B facility and receive drugs that were purchased at a discount.
Conti RM. Drug Discount Program—Reply. JAMA. 2013;310(15):1627. doi:10.1001/jama.2013.276770